APA (7th ed.) Citation

Kanellopoulos, P., Mattsson, A., Abouzayed, A., Obeid, K., Nock, B. A., Tolmachev, V., . . . Orlova, A. (2023). P-154 - Preclinical evaluation of [111In]In-labeled GRPR-targeting DB15 mimics for potential theranostic use in prostate cancer. Nuclear Medicine & Biology, 126/127, N.PAG. https://doi.org/10.1016/j.nucmedbio.2023.108624

Chicago Style (17th ed.) Citation

Kanellopoulos, Panagiotis, Adam Mattsson, Ayman Abouzayed, Karim Obeid, Berthold A. Nock, Vladimir Tolmachev, Theodosia Maina-Nock, and Anna Orlova. "P-154 - Preclinical Evaluation of [111In]In-labeled GRPR-targeting DB15 Mimics for Potential Theranostic Use in Prostate Cancer." Nuclear Medicine & Biology 126/127 (2023): N.PAG. https://doi.org/10.1016/j.nucmedbio.2023.108624.

MLA (9th ed.) Citation

Kanellopoulos, Panagiotis, et al. "P-154 - Preclinical Evaluation of [111In]In-labeled GRPR-targeting DB15 Mimics for Potential Theranostic Use in Prostate Cancer." Nuclear Medicine & Biology, vol. 126/127, 2023, p. N.PAG, https://doi.org/10.1016/j.nucmedbio.2023.108624.